Accordingly, imatinib mesylate has inhibited growth of ovarian cancer cells through PDGFRA and Akt inactivation (Matei et al, 2004), and combination therapy of imatinib–paclitaxel has impaired progression of ovarian cancer in peritoneal cavity of nude mice and lead to increased apoptosis of tumour-associated endothelial cells (Apte et al, 2004b). This evidence concerns the gene AKT1 and neoplasm.